Jeffrey Jerome Ludwig Sells 6,051 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) insider Jeffrey Jerome Ludwig sold 6,051 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $3.27, for a total value of $19,786.77. Following the transaction, the insider now directly owns 120,986 shares in the company, valued at $395,624.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Puma Biotechnology Stock Down 2.6 %

NASDAQ PBYI opened at $3.02 on Thursday. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.46 and a quick ratio of 1.38. The stock has a market capitalization of $145.68 million, a PE ratio of 9.15 and a beta of 1.09. Puma Biotechnology, Inc. has a 1 year low of $2.13 and a 1 year high of $7.73. The business’s 50-day moving average is $3.95 and its 200 day moving average is $4.79.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.12. The company had revenue of $43.80 million for the quarter, compared to analysts’ expectations of $41.53 million. Puma Biotechnology had a return on equity of 35.49% and a net margin of 6.79%. Sell-side analysts forecast that Puma Biotechnology, Inc. will post 0.22 earnings per share for the current year.

Institutional Trading of Puma Biotechnology

Several large investors have recently modified their holdings of the business. Crestline Management LP grew its stake in shares of Puma Biotechnology by 6.5% in the fourth quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 2,135 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Puma Biotechnology in the first quarter worth about $57,000. Ritholtz Wealth Management purchased a new stake in Puma Biotechnology in the fourth quarter worth about $66,000. Assenagon Asset Management S.A. lifted its holdings in Puma Biotechnology by 23.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 85,039 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 15,897 shares during the period. Finally, Jump Financial LLC lifted its holdings in Puma Biotechnology by 131.7% in the fourth quarter. Jump Financial LLC now owns 57,200 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 32,510 shares during the period. 61.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on PBYI shares. StockNews.com raised Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 12th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Monday, June 3rd.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.